n-methylscopolamine has been researched along with Diabetes Mellitus, Type 1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davidson, MB; Peters, AL | 1 |
| Davidson, MB; Harris, MD; Rosenberg, CS; Ziel, FH | 1 |
1 trial(s) available for n-methylscopolamine and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Suppression of sleep-induced growth hormone secretion by anticholinergic agent abolishes dawn phenomenon.
Topics: Blood Glucose; Catecholamines; Circadian Rhythm; Diabetes Mellitus, Type 1; Fatty Acids, Nonesterified; Glucagon; Growth Hormone; Humans; N-Methylscopolamine; Osmolar Concentration; Parasympatholytics; Scopolamine Derivatives; Sleep | 1988 |
1 other study(ies) available for n-methylscopolamine and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Inhibition of sleep-induced growth hormone secretion: no effect on diabetic control.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Growth Hormone; Humans; Insulin; Insulin Infusion Systems; N-Methylscopolamine; Parasympatholytics; Scopolamine Derivatives; Sleep | 1990 |